Paul M. Kent, MD

Medical Director of FibroFighters Foundation Associate Professor of Pediatrics, Retired
FibroFighters Foundation

Abstracts(s):

• PC3010: First Report of Naxitamab Response for Brain Metastasis in Refractory High Risk Neuroblastoma
  Monday, October 10, 2022

  1:30 PM – 2:30 PM US PDT

• PC3016: Nivolumab and Lenvatinib Immunochemotherapy in 20 Children and Young Adults with Unresectable or Metastatic Fibrolamellar Carcinoma
  Monday, October 10, 2022

  1:30 PM – 2:30 PM US PDT